Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics

Core Insights - Ardelyx reported $74.11 million in revenue for Q1 2025, a year-over-year increase of 61.1%, but fell short of the Zacks Consensus Estimate by 8.14% [1] - The company posted an EPS of -$0.17, which is a decline from -$0.11 a year ago, resulting in a surprise of -70.00% compared to the consensus estimate of -$0.10 [1] Revenue Breakdown - Product sales netted $67.81 million, below the six-analyst average estimate of $77.61 million, reflecting a year-over-year change of +55.9% [4] - Sales of IBSRELA reached $44.40 million, compared to the average estimate of $53.71 million [4] - Sales of XPHOZAH were $23.41 million, slightly below the estimated $24.55 million [4] - Product supply revenue was $0.25 million, significantly lower than the four-analyst average estimate of $3.70 million, marking a year-over-year decline of 88.1% [4] - Non-cash royalty revenue related to future royalties was $1.03 million, exceeding the average estimate of $0.68 million [4] Stock Performance - Ardelyx shares have returned +12.8% over the past month, contrasting with a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]